The CVProfilor measures the elasticity of small and large arteries to determine if patients have early stage cardiovascular disease that requires further diagnosis and treatment. The FDA approved test is inexpensive, non-invasive, quick to perform and provides immediate results.
Today in Cardiology is a monthly publication that is distributed to every cardiologist in the United States, representing over 100,000 physicians.

“Recent medical research shows blood pressure to be ineffective for measuring hypertension,” said Mark Schwartz, Chairman and CEO of the Company. “We expect that the American Society of Hypertension will revise its definition of hypertension to emphasize the vascular nature of the disease in the very near future. The evidence continues to show that the CVProfilor gives doctors the chance to identify heart disease before it results in a heart attack or stroke.”
Dr. Jay Cohn, professor of medicine at the University of Minnesota Medical School, and director of the Rasmussen Center for Cardiovascular Disease Prevention, is one of the inventors of the technology.

Cohn recently made headlines for his involvement in the creation of BiDil, marketed by NitroMed Inc., touted as the nation’s first drug for use by African American patients with heart disease.

Hypertension Diagnostics, Inc. is working to save lives by reducing the risk of vascular disease with its CVProfilor^® DO-2020 System. The CVProfilor measures the elasticity of small and large arteries, a key indicator of cardiovascular health. It is FDA approved and in use by physicians around the United States. More information is available at www.hdii.com.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2004 Annual Report on Form 10-KSB, and the subsequent Quarterly Report on Form 10-QSB, which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.

Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.

Website: www.HDII.com
 
Contact: Mark Schwartz, CEO
651-687-9999